Filing Details

Accession Number:
0001299130-21-000107
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-02 20:31:50
Reporting Period:
2021-02-26
Accepted Time:
2021-03-02 20:31:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1299130 Pacific Biosciences Of California Inc. PACB Laboratory Analytical Instruments (3826) 161590339
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1317102 Michael Hunkapiller Pacific Biosciences Of California, Inc.
1305 O'Brien Drive
Menlo Park CA 94025
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-26 109,749 $5.72 958,154 No 4 M Direct
Common Stock Acquisiton 2021-02-26 79,363 $7.87 1,037,517 No 4 M Direct
Common Stock Acquisiton 2021-02-26 45,134 $5.27 1,082,651 No 4 M Direct
Common Stock Disposition 2021-02-26 170,824 $30.69 911,827 No 4 S Direct
Common Stock Disposition 2021-02-26 43,946 $31.49 867,881 No 4 S Direct
Common Stock Disposition 2021-02-26 15,771 $32.74 852,110 No 4 S Direct
Common Stock Disposition 2021-02-26 3,705 $33.33 848,405 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-02-26 109,749 $0.00 109,749 $5.72
Common Stock Stock Option (right to buy) Disposition 2021-02-26 79,363 $0.00 79,363 $7.87
Common Stock Stock Option (right to buy) Disposition 2021-02-26 45,134 $0.00 45,134 $5.27
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-03-16 No 4 M Direct
0 2026-03-15 No 4 M Direct
0 2027-02-15 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020.
  2. This sale price represents the weighted average sale price of the shares sold ranging from $30.20 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  3. This sale price represents the weighted average sale price of the shares sold ranging from $31.20 to $32.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  4. This sale price represents the weighted average sale price of the shares sold ranging from $32.23 to $33.20 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  5. This sale price represents the weighted average sale price of the shares sold ranging from $33.23 to $33.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
  6. The shares subject to the option are fully vested and exercisable.